Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.

NCT07077616 · clinicaltrials.gov ↗
EARLY_PHASE1
Phase
RECRUITING
Status
29
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Biogenea Pharmaceuticals Ltd.

Collaborators